Mitomic™ Test for Prostate Cancer

About MDNA Life Sciences

MDNA Life Sciences is a pioneer in mitochondrial genomics, developing liquid biopsy diagnostics using its proprietary Mitomic™ Technology. Founded in 2001, the company's platform detects unique mtDNA biomarkers shed into the bloodstream by diseased cells, aiming for high accuracy, particularly in early-stage cancer detection. Its lead program is a prostate cancer test with a claimed 100% Negative Predictive Value for clinically significant cancer, positioning it to address critical unmet needs in difficult-to-diagnose conditions. The company operates as a private entity in the diagnostics sector, targeting a significant market opportunity with its non-invasive testing approach.

Therapeutic Areas

Other Prostate Cancer Drugs